Related references
Note: Only part of the references are listed.A2A adenosine receptors and Parkinson's disease severity
I. Casetta et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b
Izaskun Villar-Menendez et al.
NEUROBIOLOGY OF DISEASE (2014)
Parkinson's disease pharmacogenomics: new findings and perspectives
Artur F. Schumacher-Schuh et al.
PHARMACOGENOMICS (2014)
Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients
A. F. Schumacher-Schuh et al.
PHARMACOGENOMICS JOURNAL (2014)
New insights into the mechanism of drug-induced dyskinesia
Anton J. M. Loonen et al.
CNS SPECTRUMS (2013)
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Lorraine V. Kalia et al.
MOVEMENT DISORDERS (2013)
Adenosine receptors as drug targets - what are the challenges?
Jiang-Fan Chen et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Effects of adenosine A2a receptor agonist and antagonist on hippocampal nuclear factor-kB expression preceded by MDMA toxicity
Fatemeh Kermanian et al.
METABOLIC BRAIN DISEASE (2013)
The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease
Philippe Huot et al.
PHARMACOLOGICAL REVIEWS (2013)
Adenosine A2A Antagonists in Parkinson's Disease: What's Next?
Patrick Hickey et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
Adenosine A2A-Receptor Antagonism and Pathophysiology of Parkinson's Disease and Drug-Induced Movement Disorders
Jaime Kulisevsky et al.
EUROPEAN NEUROLOGY (2012)
Differential effects of ADORA2A gene variations in pre-attentive visual sensory memory subprocesses
Christian Beste et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients
Mariana Rieck et al.
PHARMACOGENOMICS (2012)
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
S. A. Ivanova et al.
TRANSLATIONAL PSYCHIATRY (2012)
Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies
Catherine J. Wei et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2011)
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease
R. A. Popat et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease
Alessandro Tozzi et al.
JOURNAL OF NEUROSCIENCE (2011)
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
A. F. Ramlackhansingh et al.
NEUROLOGY (2011)
Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients
Masahiro Mishina et al.
PLOS ONE (2011)
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Marie Therese Armentero et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Genetic Associations of Brain Structural Networks in Schizophrenia: A Preliminary Study
Kanchana Jagannathan et al.
BIOLOGICAL PSYCHIATRY (2010)
Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder
Christine M. Freitag et al.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY (2010)
A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson's disease
Katia Varani et al.
FASEB JOURNAL (2010)
Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality
Christa Hohoff et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2010)
Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations
Carlo Colosimo et al.
MOVEMENT DISORDERS (2010)
Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption
Peter J. Rogers et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety
Emma Childs et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Adenosine A2A receptors and basal ganglia physiology
S. N. Schiffmann et al.
PROGRESS IN NEUROBIOLOGY (2007)
Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications
Micaela Morelli et al.
PROGRESS IN NEUROBIOLOGY (2007)
Adenosine A2A receptors and brain injury:: Broad spectrum of neuroprotection, multifaceted actions and fine tuning modulation
Jiang-Fan Chen et al.
PROGRESS IN NEUROBIOLOGY (2007)
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission
Alessandro Tozzi et al.
NEUROPHARMACOLOGY (2007)
Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function
Kjell Fuxe et al.
PHYSIOLOGY & BEHAVIOR (2007)
Identification and characterization of two nuclear factor-κB sites in the regulatory region of the dopamine D2 receptor
Sandra Bontempi et al.
ENDOCRINOLOGY (2007)
PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes
Lucia Conde et al.
NUCLEIC ACIDS RESEARCH (2006)
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990
JA Van Gerpen et al.
ARCHIVES OF NEUROLOGY (2006)
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
J Jankovic
MOVEMENT DISORDERS (2005)
Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation
M Stephens et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses
LQ Yu et al.
BRAIN RESEARCH (2004)
Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies
S Greenland
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease
M Ochi et al.
NEUROSCIENCE (2004)
Triplex-forming oligonucleotides - Sequence-specific DNA ligands as tools for gene inhibition and for modulation of DNA-associated functions
R Besch et al.
CURRENT DRUG TARGETS (2004)
Triplex-forming oligonucleotide target sequences in the human genome
JR Goni et al.
NUCLEIC ACIDS RESEARCH (2004)
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
F Calon et al.
BRAIN (2004)
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease
F Bibbiani et al.
EXPERIMENTAL NEUROLOGY (2003)
Triplex-forming oligonucleotides as modulators of gene expression
RV Guntaka et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2003)
Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells
ND Khoa et al.
JOURNAL OF IMMUNOLOGY (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
A new statistical method for haplotype reconstruction from population data
M Stephens et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: A microdialysis study
M Ochi et al.
NEUROSCIENCE (2000)
Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review
Evita Evangelia Christou et al.
SEMINARS IN OPHTHALMOLOGY
Share Paper
